Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGL-270 + Adebrelimab in NSCLC
NCT06685653Phase 1Not yet recruiting
- Sponsor
- Nanjing Tianyinshan Hospital
- Primary completion
- Nov 2026
- Modality
- Vaccine mRNA, mRNA Vaccines, Therapeutic Vaccines
01
Overview
Phase 1, open-label trial of RGL-270 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nanjing Tianyinshan Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days and Safety endpoints at 90 days. Status: not yet recruiting.
02
Drugs
RGL-270
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06685653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685653.